Katherine E. Hanlon, Ph.D.
Affiliations: | 2012 | Medical Pharmacology | University of Arizona, Tucson, AZ |
Area:
Pain, opioids, pharmacologyGoogle:
"Katherine Hanlon"Mean distance: 17.73 (cluster 32) | S | N | B | C | P |
Parents
Sign in to add mentor| Todd W. Vanderah | grad student | 2012 | University of Arizona | |
| (Cannabinoid receptor 2: A novel multi-targeted approach in the treatment of breast cancer and related skeletal metastasis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bove GM, Chapelle SL, Hanlon KE, et al. (2017) Attenuation of postoperative adhesions using a modeled manual therapy. Plos One. 12: e0178407 |
| Hanlon KE, Lozano-Ondoua AN, Umaretiya PJ, et al. (2016) Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent. Breast Cancer (Dove Medical Press). 8: 59-71 |
| Arabatzis T, Littlefield T, Watson J, et al. (2015) Modifying tumor associated macrophage function through cannabinoid receptor 2. Journal For Immunotherapy of Cancer. 3: 291 |
| Largent-Milnes TM, Brookshire SW, Skinner DP, et al. (2013) Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. The Journal of Pharmacology and Experimental Therapeutics. 347: 7-19 |
| Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, et al. (2013) Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 92-107 |
| Hanlon KE. (2012) Cannabinoid Receptor 2: A Novel Multi-Targeted Approach in the Treatment of Breast Cancer and Related Skeletal Metastasis The Journal of Pain. 13 |
| Ondoua A, Rodriquez J, Hanlon K, et al. (2012) Multivalent cathepsin inhibitor, VBY-825, attenuates breast-cancer induced bone remodeling and pain The Journal of Pain. 13: S43 |
| Hanlon KE, Herman DS, Agnes RS, et al. (2011) Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Brain Research. 1395: 1-11 |
| Lee YS, Kulkarani V, Cowell SM, et al. (2011) Development of potent μ and δ opioid agonists with high lipophilicity. Journal of Medicinal Chemistry. 54: 382-6 |
| Holsinger LJ, Ondoua-Lozano A, Rodriguez J, et al. (2011) Abstract A219: Efficacy of a spectrum-selective cathepsin inhibitor in a mouse model of bone cancer. Molecular Cancer Therapeutics. 10 |